Home Cart Sign in  
Chemical Structure| 2414572-47-5 Chemical Structure| 2414572-47-5

Structure of Tuxobertinib
CAS No.: 2414572-47-5

Chemical Structure| 2414572-47-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Tuxobertinib is an inhibitor targeting EGFR and HER2 allosteric mutations, showing significant anti-tumor effects in the treatment of various cancers.

Synonyms: BDTX-189

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Tuxobertinib

CAS No. :2414572-47-5
Formula : C29H29ClN6O4
M.W : 561.03
SMILES Code : O=C(NC1=CC2=C(NC3=CC=C(C(Cl)=C3)OCC4=NC=CC=C4)N=CN=C2C=C1OCCN5CCOCC5)C=C
Synonyms :
BDTX-189
MDL No. :MFCD32878264

Safety of Tuxobertinib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Related Pathways of Tuxobertinib

RTK
JAK-STAT

Isoform Comparison

Biological Activity

Description
Tuxobertinib (BDTX-189) serves as a powerful, orally administered, selective inhibitor targeting allosteric EGFR and HER2 oncogenic mutations, notably EGFR/HER2 exon 20 insertion mutants. It demonstrates dissociation constants (KDs) of 0.2, 0.76, 13, and 1.2 nM for EGFR, HER2, BLK, and RIPK2, respectively, and exhibits anticancer activity[1].
Target
  • EGFR/ErbB1

    EGFR, Kd:0.2 nM

  • HER2/ErbB2

    HER2, Kd:0.76 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
AML12 hepatocytes 10 μM 6 h To investigate the effect of BDTX-189 on EGFR signaling pathway, results showed that BDTX-189 inhibited EGFR phosphorylation PMC9903539

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT04209465 Solid Tumor PHASE1|PHASE2 TERMINATED 2022-09-16 9250, Scottsdale, Arizona, 852... More >>58, United States|9405, Long Beach, California, 90813, United States|9474, Orange, California, 92868, United States|7141, New Haven, Connecticut, 06520, United States|4080, Lake Mary, Florida, 32746, United States|4100, Orlando, Florida, 32827, United States|9535, Plantation, Florida, 33322, United States|4060, Sarasota, Florida, 34232, United States|9035, Atlanta, Georgia, 30322, United States|9530, Rolling Meadows, Illinois, 60008, United States|9092, New Orleans, Louisiana, 70112, United States|9203, Boston, Massachusetts, 02215, United States|9209, Buffalo, New York, 14263, United States|9215, New York, New York, 10016, United States|9236, New York, New York, 10065, United States|9264, Portland, Oregon, 97213, United States|7122, Pittsburgh, Pennsylvania, 15232, United States|4107, Chattanooga, Tennessee, 37404, United States|3000, Nashville, Tennessee, 37203, United States|9003, Dallas, Texas, 75390, United States|9117, Houston, Texas, 77030, United States|9538, Webster, Texas, 77598, United States|9112, Fairfax, Virginia, 22031, United States|9173, Milwaukee, Wisconsin, 53226, United States|9500, Copenhagen, Denmark|9501, Bordeau, 33000, France|9525, Lille, 59000, France|9373, Lyon, 69008, France|9512, Poitiers, 86021, France|9476, Rennes, 44229, France|9496, Barcelona, 08028, Spain|9363, Barcelona, 08035, Spain|9508, Barcelona, 08036, Spain|9429, Madrid, 28007, Spain|9495, Madrid, 28040, Spain|9383, Madrid, 28041, Spain|9382, Madrid, 28050, Spain|9510, Valencia, 46010, Spain Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.78mL

0.36mL

0.18mL

8.91mL

1.78mL

0.89mL

17.82mL

3.56mL

1.78mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories